Multicenter analysis of more than 300 very elderly non-Hodgkin lymphoma (NHL) patients (pts): Impact of comorbidities and functional status on outcome.
C. Nabhan , S. M. Smith , I. B. Helenowski , E. E. Ramsdale
Journal of Clinical Oncology 29 8042 -8042
2011
Herbal supplements: Boon or bane for older cancer patients?
J. M. Mckoy , A. S. Haleem , D. B. Liebling
Journal of Clinical Oncology 29
1
2011
Gardasil: A false sense of immunity?
M. Boen , D. DeLeon , C. L. Bennett , A. T. Samaras
Journal of Clinical Oncology 28
1
2010
Patient (PT) understanding of venous thromboembolism (VTE) risks associated with lenalidomide (Len) and thalidomide (Thal), previous clots, and current prophylaxis.
D. M. Courtney , A. T. Samaras , J. Titus , J. M. Mckoy
Journal of Clinical Oncology 28
2010
Hip fractures as a complication of cancer care in perimenopausal women with breast cancer.
B. J. Edwards , W. J. Gradishar , D. W. Raisch , A. Bunta
Journal of Clinical Oncology 28 ( 15_suppl) e11086 -e11086
2010
RADAR assessment of quality of reporting of serious adverse drug reactions (sADRs) to an Institutional Review Board (IRB) for 14 clinical trials with imatinib mesylate
C. L. Bennett , J. L. Lagman , J. M. McKoy , D. M. Courtney
Journal of Clinical Oncology 26 6588 -6588
2008
The importance of timely and appropriately-sized pharmacovigilance studies in the detection of safety signals: Lessons learned from the erythropoiesis stimulating agents (ESAs) controversy
M. Henke , C. L. Bennett , J. M. McKoy , B. J. Edwards
Journal of Clinical Oncology 26 6532 -6532
2008
Erythropoiesis stimulating agents (ESAs): An overview of safety-related findings from the Research on Adverse Drug Events and Reports (RADAR) project
J. M. McKoy , A. O. Sartor , M. Henke , D. P. West
Journal of Clinical Oncology 26 6635 -6635
2008
Quality not quantity: Key success factors from the first decade of safety reports from the Research on Adverse Drug Events and Reports project (RADAR)
C. Bennett , B. J. Edwards , C. C. Tigue , D. W. Raisch
Journal of Clinical Oncology 27 6559 -6559
2009
Defining the role of patient navigators for men with an abnormal prostate cancer screening test result in an urban setting
S. Hamer , N. J. Nonzee , M. A. Simon , D. Liu
Journal of Clinical Oncology 27 ( 15_suppl) 5120 -5120
2009
Erythropoiesis-stimulating agents for cancer patients: Increasingly restrictive guidelines and policies in the United States and Europe
A. T. Samaras , S. Y. Lai , B. Kim , D. P. West
Journal of Clinical Oncology 27
2009
Systematic review of toxicities of lineage-specific hematopoietic growth factors toxicities: Implications for biosimilar erythropoietins, thromopoietic receptor agonists, and continuous erythropoietin receptor agonists
A. Polish , A. T. Samaras , J. M. McKoy , D. P. West
Journal of Clinical Oncology 27
2009
Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?
A. J. Lurie , B. Djulbegovic , J. R. Nebeker , C. Angelotta
Journal of Clinical Oncology 24 6026 -6026
1
2006
Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia
C. Angelotta , J. M. McKoy , M. J. Fisher , C. G. Buffie
Vox Sanguinis 93 ( 2) 159 -165
12
2007
Elevated incidence of fractures in women with invasive breast cancer
B. J. Edwards , W. J. Gradishar , M. E. Smith , J. A. Pacheco
Osteoporosis International 27 ( 2) 499 -507
13
2016
The role of health literacy in patient navigation intensity prior to and post-prostate cancer diagnosis
M. A. Simon , N. J. Nonzee , J. M. McKoy , A. Rademaker
Journal of Clinical Oncology 26 17534 -17534
2008
Tumor progression and mortality associated with administration of erythropoiesis stimulating agents (ESAs) to cancer patients: Is toxicity due to ESAs or elevated hemoglobin (Hgb) levels
A. Kuykendal , C. L. Bennett , J. M. McKoy , S. Boyle
Journal of Clinical Oncology 26 11115 -11115
1
2008
Report card for accelerated FDA approval oncology drugs (1995- 2003): Is it time for a make-up test?
S. M. Belknap , E. A. Lyons , J. M. McKoy , C. L. Bennett
Journal of Clinical Oncology 22 6002 -6002
2
2004
Reporting of cancer clinical trial adverse drug events: A RADAR report.
S. M. Belknap , C. H. Georgopoulos , S. A. Weitzman , L. Qualkenbush
Journal of Clinical Oncology 29 6090 -6090
2011
Bisphosphonates and acute kidney injury in cancer patients: A RADAR report.
B. J. Edwards , S. Usmani , A. T. Samaras , J. M. McKoy
Journal of Clinical Oncology 29
2011